PriceTargets.com logo

Arcutis Biotherapeutics - ARQT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $34.00
  • Forecasted Upside: 52.88%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$22.24 As of 03/18/2026 05:00 PM ET
▼ -0.48 (-2.11%)

This chart shows the closing price for ARQT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcutis Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARQT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARQT

Analyst Price Target is $34.00
▲ +52.88% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $34.00, with a high forecast of $36.00 and a low forecast of $29.00. The average price target represents a 52.88% upside from the last price of $22.24.

This chart shows the closing price for ARQT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Arcutis Biotherapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/16/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/2/2026MizuhoLower TargetOutperform ➝ Outperform$37.00 ➝ $35.00
2/27/2026GuggenheimBoost TargetBuy ➝ Buy$34.00 ➝ $35.00
2/26/2026HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $34.00
2/26/2026TD CowenBoost TargetBuy ➝ Buy$30.00 ➝ $35.00
2/26/2026Needham & Company LLCBoost TargetBuy ➝ Buy$31.00 ➝ $36.00
1/26/2026Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $31.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/29/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/28/2025MizuhoBoost TargetOutperform ➝ Outperform$32.00 ➝ $37.00
10/30/2025The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$19.00 ➝ $29.00
10/29/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00
10/29/2025MizuhoSet Target$32.00
10/29/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/28/2025Needham & Company LLCBoost TargetBuy ➝ Buy$22.00 ➝ $30.00
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/7/2025TD CowenReiterated RatingBuy ➝ Buy
8/7/2025Needham & Company LLCBoost TargetBuy ➝ Buy$20.00 ➝ $22.00
7/25/2025The Goldman Sachs GroupInitiated CoverageNeutral$18.00
5/23/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$20.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/3/2025GuggenheimReiterated RatingBuy ➝ Buy
4/3/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
3/11/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$16.00 ➝ $19.00
2/27/2025The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$13.00 ➝ $15.00
2/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
2/26/2025MizuhoBoost TargetOutperform ➝ Outperform$20.00 ➝ $21.00
2/26/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
2/24/2025GuggenheimReiterated RatingBuy ➝ Buy
2/10/2025GuggenheimReiterated RatingBuy ➝ Buy
1/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
1/7/2025MizuhoBoost TargetOutperform ➝ Outperform$19.00 ➝ $20.00
12/30/2024HC WainwrightInitiated CoverageBuy$19.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
8/28/2024Jefferies Financial GroupInitiated CoverageBuy$15.00
8/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
7/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
7/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
5/15/2024Needham & Company LLCBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
5/15/2024MizuhoBoost TargetBuy ➝ Buy$17.00 ➝ $18.00
4/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$16.00
2/28/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$6.00 ➝ $11.00
2/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$8.00 ➝ $16.00
2/23/2024MizuhoReiterated RatingBuy ➝ Buy$8.00 ➝ $16.00
1/2/2024MizuhoUpgradeNeutral ➝ Buy$4.00 ➝ $8.00
11/13/2023Morgan StanleyLower TargetOverweight ➝ Overweight$45.00 ➝ $10.00
11/8/2023JonesTradingReiterated RatingBuy ➝ Hold
11/6/2023HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $8.00
11/6/2023Needham & Company LLCLower TargetBuy ➝ Buy$22.00 ➝ $8.00
10/26/2023MizuhoDowngradeBuy ➝ Neutral
10/13/2023The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$32.00 ➝ $6.00
9/25/2023MizuhoReiterated RatingBuy ➝ Buy$57.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
8/9/2023TD CowenLower TargetOutperform ➝ Outperform$65.00 ➝ $50.00
7/17/2023GuggenheimLower Target$45.00 ➝ $38.00
6/12/2023500.comReiterated RatingReiterates
5/26/2023Truist FinancialLower Target$45.00 ➝ $40.00
5/10/2023MizuhoLower Target$61.00 ➝ $57.00
4/19/2023Needham & Company LLCReiterated RatingBuy$24.00
4/12/2023Morgan StanleyLower TargetOverweight$50.00 ➝ $47.00
4/11/2023MizuhoReiterated RatingBuy$61.00
3/29/2023Truist FinancialLower TargetBuy$50.00 ➝ $45.00
3/16/2023Needham & Company LLCLower TargetBuy$46.00 ➝ $24.00
3/1/2023Cantor FitzgeraldReiterated RatingOverweight
3/1/2023Needham & Company LLCReiterated RatingBuy$46.00
3/1/2023Morgan StanleyLower TargetOverweight$51.00 ➝ $50.00
12/13/2022Morgan StanleyBoost TargetOverweight$49.00 ➝ $51.00
10/4/2022Morgan StanleyBoost TargetOverweight$46.00 ➝ $49.00
9/27/2022Morgan StanleyBoost TargetOverweight$45.00 ➝ $46.00
9/22/2022JonesTradingReiterated RatingBuy$54.00
9/7/2022Needham & Company LLCInitiated CoverageBuy$46.00
8/2/2022The Goldman Sachs GroupBoost TargetBuy$45.00 ➝ $50.00
8/2/2022Morgan StanleyBoost TargetOverweight$39.00 ➝ $45.00
6/7/2022Morgan StanleyBoost TargetOverweight$36.00 ➝ $39.00
4/7/2022MizuhoLower TargetBuy$58.00 ➝ $57.00
3/25/2022MizuhoReiterated RatingBuy$58.00
3/17/2022The Goldman Sachs GroupInitiated CoverageBuy$45.00
3/2/2022Morgan StanleyBoost TargetOverweight$35.00 ➝ $37.00
2/23/2022Cantor FitzgeraldReiterated RatingOverweight
12/23/2021MizuhoReiterated RatingBuy$58.00
11/19/2021Morgan StanleyLower TargetOverweight$50.00 ➝ $35.00
10/1/2021MizuhoReiterated RatingBuy$58.00
7/16/2021Morgan StanleyLower TargetOverweight$52.00 ➝ $50.00
6/29/2021MizuhoInitiated CoverageBuy$58.00
5/27/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$52.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 13 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 21 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 21 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Arcutis Biotherapeutics logo
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More

Today's Range

Now: $22.24
Low: $22.20
High: $22.84

50 Day Range

MA: $25.80
Low: $22.24
High: $29.88

52 Week Range

Now: $22.24
Low: $11.86
High: $31.77

Volume

1,984,748 shs

Average Volume

1,455,797 shs

Market Capitalization

$2.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcutis Biotherapeutics?

The following equities research analysts have issued stock ratings on Arcutis Biotherapeutics in the last twelve months: Guggenheim, HC Wainwright, Mizuho, Needham & Company LLC, TD Cowen, The Goldman Sachs Group, Inc., Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ARQT.

What is the current price target for Arcutis Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for Arcutis Biotherapeutics in the last year. Their average twelve-month price target is $34.00, suggesting a possible upside of 52.9%. Needham & Company LLC has the highest price target set, predicting ARQT will reach $36.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $29.00 for Arcutis Biotherapeutics in the next year.
View the latest price targets for ARQT.

What is the current consensus analyst rating for Arcutis Biotherapeutics?

Arcutis Biotherapeutics currently has 1 sell rating, 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARQT.

What other companies compete with Arcutis Biotherapeutics?

Other companies that are similar to Arcutis Biotherapeutics include Regencell Bioscience, Dr. Reddy's Laboratories, Elanco Animal Health, Abivax and Qiagen. Learn More about companies similar to Arcutis Biotherapeutics.

How do I contact Arcutis Biotherapeutics' investor relations team?

Arcutis Biotherapeutics' physical mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company's listed phone number is 805-418-5006 and its investor relations email address is [email protected]. The official website for Arcutis Biotherapeutics is www.arcutis.com. Learn More about contacing Arcutis Biotherapeutics investor relations.